About Nucleolar pre-ribosomal-associated protein 1
Nucleolar pre-ribosomal-associated protein 1 (URB1) is a protein
from Homo sapiens identified by UniProt accession
O60287, 2271 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Nucleolar pre-ribosomal-associated protein 1 |
| UniProt accession | O60287 |
| Gene | URB1 |
| Organism | Homo sapiens |
| Length | 2271 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- testosterone measurement · score 0.27
- familial glucocorticoid deficiency · score 0.18
- genetic disorder · score 0.18
- motor neuron disease · score 0.09
- major depressive disorder · score 0.06
- serum gamma-glutamyl transferase measurement · score 0.04
- serum alanine aminotransferase measurement · score 0.04
- blood protein measurement · score 0.02
- cancer · score 0.02
- hepatocellular carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60287-F1 | alphafold | PREDICTED | 75.04 | — |
Amino-acid sequence (2271 residues)
MGVPKRKASG GQDGAASSAG AAKRARKEEL TGVRFKAQLK DPQGPGPGLE AFVSAAKKLP REDVYDVVEG YIKISVECVE IFQLLSGEKR PESETMLIFQ VFEAILLRTA SDLSHFHVVG TNIVKKLMNN HMKLICESLY ASGYRLARAC LSLMTAMVTQ GPEAARDVCS HFDLNKKTLY TLVTKRDSKG VYDVRQAYVQ FALSFLIAGD DSTIVQVLEV KEFIPCIFSS GIKEDRISTI NILLSTLKTK VVHNKNITKT QKVRFFTGQL LNHIASLYNW NGITDVNPEN VKVSAEEAGK TMVRELVHNF LMDLCCSLKH GINFYDASLG TFGRGGNLTL LHFLLGLKTA ADDDLVADLV VNILKVCPDL LNKYFKEVTF SFIPRAKSTW LNNIKLLNKI YEAQPEISRA FQTREFIPLP RLLAMVMVTT VPLVCNKSMF TQALNLDSTS VRHTALSLIS VILKRALKTV DHCLNKEVWQ ESGVYTAVMM EEFVQLFREA LSKILPDLNT VVWVWQSLKK QETKQDDKKG QKRSDGPPAA CDAHQCDDAE TILLKAVLLQ VICLYQKVVP HVVMQYNFDF SKLLKGVISE QGLREEVPPI LQHHMLKVAL ELPASKFLWL KAQEGPDAEI IGGERSVFYL LMKMFVTSSH LQLKSLTKLL IMKILRDTGV FEHTWKELEL WLEHLENTME EDKETVIQFL ERILLTLVAN PYSYTDKASD FVQEASMLQA TMTKQEADDM SIPISHIDDV LDMVDVLVEG SEGLDEEIGF TLSEDMILLT FPFSAVVPAA LEARNKLLLG TGNEAAENVV TYLTAVLTDL LHTQRDPLAL CLLLQAYDKL EPPCLVPCCQ QLSRFNRYYS LWIPEQAREA WLLQAQGSPS PPALPLASSF TALLQAAYES QALRDEHIQV QLQATMPHLS MQQVLLAAKQ VLLYLRSTVE NFGQLGRSVG PPLLQLFLDL LRRLVVHCEQ LDAQNQQRCE AARAEADLFL DMESVASLEL ANDQTLEEVL VAILRHPTLE GWFLALEQQA LPPHTLSPVL VKLLATHFSA GVLQLLAASA PILQNIGQLG LLARYSEAIT QSVLKELQNR RAGPATSPPK TPPQLEALQE LHPYMEGAQL REVTLALLSL PETHLVTQQP TKSPGKERHL NALGKTLVQL LTCSPQDQLQ SGELLWSSEY VRGLGALLPT LAVDELDTVL LHTLQRDPVL APAVGADLLD YCLARRTQAA LSIAALLLQE SCTHLLWFEQ WCLQAGPGLG LQGDLDDFLP LIHVYLQCRT RSHFTRPAGV SSAVIPVLRK TLWRQLQSRL LSTDSPPASG LYQEILAQLV PFARAKDLSV LMDRLPSLLH TPSSHKRWIV ADSISAALEG SAEELCAWRR TLLESCVKWL IVSFSGGQQD DDNTQNQEKE MLLRLNALLH ALNEVDPGDW QKFVKKGLKF RYQDHTFLKM LLTAVQLLYS PESSVRTKLI QLPVVYVMLM QHSLFLPTLL TSDGEESPDS QVKEALVDLM LTVVEMCPSV CESSHFAVLL GAYGATLSVL DQKILLLLRA YEQNKLSLIN FRVLLWGPAA VEHHKTCRSL GRSLWQQPSV GDILRLLDRD RMMQTILHFP QNRRLLPPED TQELIFKDKS RVDLDGLYDP CFLLQLFSEL TRPEFVVDCR KFLDSNALGL TVTALSSYDP QMRAIAYHVL AAYYSHLEGA RFQEQSQLLY LLDVVRNGIR TQDMRLTFTL ALFIAKAALQ ILKPEEHMYL KVSNFLLSHE YLNMDKVPGF YQFFYSSDFE QKTEQKWVFG VLRQGIRDKQ CYELCARRGI FHIILSFFHS PLCDEAAQNW ILEILQNAAQ VARSAYEIIR DYSLLTWILH ILESKFLETP LLSNVISLLH TLWVTNLGDK AVEWESQRLC QPSSQEPAKR LALHLVNEFL YVLIVLMKHL RPTLAPVQLT NFFGTLDSVL RYRATVIQAF RDMNRFTVNE TVLSTKDVLV LLHKWSLIER DLKLQEDLRA AIEKAQAREL MKMLKDKNKP VMPARAKGPR GRKRRPGEAE EMADPELMAS TLETCKGLLR SILTYWRPVI PGPDPTQEPV DSASPESDAP GPVYAAASLA VSWVLRSVAE HPLSRAEAAG LIGWLKSHIL PHPVVVADLL KDSAVRSSIF RLYSRLCGAE GLAGPVQEVA CLFNTVMLQL VAAQGRAGSP FHPAMEALSL SSLSEKDEAT QASAAFLVSL YIKDIWLGAQ RPDTLLTHVR MVCEAADDAP SSEEEAIVVL CKDAASAASD A
Explore Nucleolar pre-ribosomal-associated protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets